Research Topics
| Evguenia S SvarovskaiaSummaryAffiliation: Gilead Sciences Country: USA Publications
| Collaborators
|
Detail Information
Publications
Low-level K65R mutation in HIV-1 reverse transcriptase of treatment-experienced patients exposed to abacavir or didanosineEvguenia S Svarovskaia
Gilead Sciences, Inc, Durham, NC, USA
J Acquir Immune Defic Syndr 46:174-80. 2007..Prior abacavir (ABC) or didanosine (ddI) therapy can result in the L74V/I or K65R mutation in HIV-1 reverse transcriptase. Preexisting K65R may have an impact on the treatment response to tenofovir disoproxil fumarate (TDF)...
The triple combination of tenofovir, emtricitabine and efavirenz shows synergistic anti-HIV-1 activity in vitro: a mechanism of action studyJoy Y Feng
Gilead Sciences, Inc, 333 Lakeside Drive, Foster City, California 94404, USA
Retrovirology 6:44. 2009....- Abundant drug-resistant NS3 mutants detected by deep sequencing in hepatitis C virus-infected patients undergoing NS3 protease inhibitor monotherapyEvguenia S Svarovskaia
Gilead Sciences, Inc, Foster City, CA, USA
J Clin Microbiol 50:3267-74. 2012..6 to 3.8 log(10) with NS3 protease inhibitor monotherapy that does not suppress the identified preexisting NS3 DRMs and thus a need for a combination therapy... 
The A62V and S68G mutations in HIV-1 reverse transcriptase partially restore the replication defect associated with the K65R mutationEvguenia S Svarovskaia
Gilead Sciences, Inc, 4 University Place, 4611 University Drive, Durham, NC 27707, USA
J Acquir Immune Defic Syndr 48:428-36. 2008..In clinical isolates, K65R is frequently accompanied by the A62V and S68G reverse transcriptase mutations...- MultiCode-RTx real-time PCR system for detection of subpopulations of K65R human immunodeficiency virus type 1 reverse transcriptase mutant viruses in clinical samplesEvguenia S Svarovskaia
Gilead Sciences, Inc, 4 University Place, 4611 University Drive, Durham, NC 27707, USA
J Clin Microbiol 44:4237-41. 2006..Fifty-three treatment-naïve and 20 treatment-experienced specimens were successfully genotyped with the new method. Results were in agreement with population sequencing and the labor-intensive single-genome sequencing method... - Mutations in the thumb-connection and RNase H domain of HIV type-1 reverse transcriptase of antiretroviral treatment-experienced patientsJoshua M Waters
Gilead Sciences, Inc, Durham, NC, USA
Antivir Ther 14:231-9. 2009..Antiretroviral therapy that targets HIV type-1 (HIV-1) reverse transcriptase (RT) can be linked to mutations in the thumb-connection (amino acids [AA] 241-426) and RNase H (AA 427-560) domains, which could affect drug resistance... - Low level of the K103N HIV-1 above a threshold is associated with virological failure in treatment-naive individuals undergoing efavirenz-containing therapyDerrick D Goodman
Gilead Sciences Inc, Durham, North Carolina, USA
AIDS 25:325-33. 2011..Here, we analyzed whether the presence of low levels of K103N at baseline correlated with virologic failure... - Allele-specific real-time PCR system for detection of subpopulations of genotype 1a and 1b hepatitis C NS5B Y448H mutant viruses in clinical samplesAndrew S Bae
Gilead Sciences, Inc, 333 Lakeside Drive, Foster City, CA 94404, USA
J Clin Microbiol 49:3168-74. 2011..5% to 3.0% detected in 5/62 (8%) treatment-naïve patient samples. These findings suggest the need for combination therapy with HCV-specific inhibitors to avoid viral rebound of preexisting mutant HCV... - Human immunodeficiency virus type 1 cDNAs produced in the presence of APOBEC3G exhibit defects in plus-strand DNA transfer and integrationJean L Mbisa
HIV Drug Resistance Program, SAIC Frederick, Inc, National Cancer Institute Frederick, Frederick, MD 21702 1201, USA
J Virol 81:7099-110. 2007..These novel observations suggest that HIV-1 cDNA produced in the presence of A3G exhibits defects in primer tRNA processing, plus-strand DNA transfer, and integration... - No resistance to tenofovir disoproxil fumarate detected after up to 144 weeks of therapy in patients monoinfected with chronic hepatitis B virusAndrea Snow-Lampart
Gilead Sciences, Incorporated, Durham, NC, USA
Hepatology 53:763-73. 2011..CONCLUSION: No nucleoside-naive or nucleoside-experienced patient developed HBV pol/RT mutations associated with TDF resistance after up to 144 weeks of exposure to TDF monotherapy... - Human apolipoprotein B mRNA-editing enzyme-catalytic polypeptide-like 3G (APOBEC3G) is incorporated into HIV-1 virions through interactions with viral and nonviral RNAsEvguenia S Svarovskaia
HIV Drug Resistance Program and AIDS Vaccine Program, Science Applications International Corporation Frederick, Inc, NCI Frederick, National Institutes of Health, Frederick, Maryland 21702, USA
J Biol Chem 279:35822-8. 2004.... - Antiretroviral drug resistance mutations in human immunodeficiency virus type 1 reverse transcriptase increase template-switching frequencyGalina N Nikolenko
HIV Drug Resistance Program, NCI-Frederick, Bldg. 535, Rm. 334, Frederick, MD 21702, USA
J Virol 78:8761-70. 2004..These results also indicate that mutations conferring resistance to antiviral drugs can increase the frequency of RT template switching and may influence the rate of retroviral recombination and viral evolution... - Azido-containing diketo acid derivatives inhibit human immunodeficiency virus type 1 integrase in vivo and influence the frequency of deletions at two-long-terminal-repeat-circle junctionsEvguenia S Svarovskaia
HIV Drug Resistance Program. Laboratory of Medicinal Chemistry, Center for Cancer Research, National Cancer Institute at Frederick, Frederick, Maryland 21702, USA
J Virol 78:3210-22. 2004..Thus, sequencing analysis of 2-LTR-circle junctions can elucidate the intracellular mechanisms of action of HIV-1 IN inhibitors... - A single amino acid substitution in human APOBEC3G antiretroviral enzyme confers resistance to HIV-1 virion infectivity factor-induced depletionHongzhan Xu
HIV Drug Resistance Program, National Cancer Institute, National Institutes of Health, Frederick, MD 21702, USA
Proc Natl Acad Sci U S A 101:5652-7. 2004..The HIV-1 Vif-resistant mutant APOBEC3G could provide a gene therapy approach to combat HIV-1 infection... - Structure activity of 3-aryl-1,3-diketo-containing compounds as HIV-1 integrase inhibitorsGodwin C G Pais
Laboratory of Medicinal Chemistry, Laboratory of Molecular Pharmacology, and HIV Drug Resistance Program, Center for Cancer Research, National Cancer Institute/NIH, 376 Boyles Street, Frederick, MD 21702-1201, USA
J Med Chem 45:3184-94. 2002..Interestingly, several analogues of L-708,906 with varied substituents on the left side aryl ring, while having good inhibitory potencies against IN in extracellular assays, are not antiviral in whole-cell systems...